A drug trial for immune-related kidney diseases
Part of Immune system & allergy clinical trials.
This trial tests an investigational drug (STR-P004) given by IV to treat kidney diseases caused by the immune system. It aims to see if the drug is safe and tolerable for patients with conditions like lupus nephritis or ANCA vasculitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of kidney disease caused by your immune system, such as lupus nephritis or ANCA vasculitis.
- A blood test must show that you have specific immune cells called CD19-positive B cells.
- Your kidneys, liver, and blood counts must be working well enough, as checked by standard lab tests.
- You cannot have other serious medical conditions, such as severe infections, heart problems, or uncontrolled seizures.
- If you could become pregnant, you must use effective birth control for 1 year after the study drug infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety of a new treatment called STR-P004 for people with systemic lupus erythematosus (SLE) or certain inflammatory muscle diseases that have not improved with standard therapies. It may be an option if your condition is hard to control.
This trial tests a new drug, STR-P005, for people with autoimmune diseases. It aims to see if the drug is safe and helps by targeting B cells that have a specific marker called CD19.
This early-stage trial tests a new cell-targeting treatment called STR-P005 in adults with lupus. The study will check whether it is safe and how well it works for people with lupus who have a specific type of immune cell (CD19-positive B cells) in their blood.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.